help me understand dose escalation, I have read the wiki twice
Genuine question, and the title is the question: help me understand dose escalation, I have read the wiki twice.
The constipation profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.
Trial names corrected in the title.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
the escalation is where most of the reported trouble sits
What do you think the glucagon component is adding, specifically?
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.